Koers Rapid Therapeutic Science Laboratories, Inc. Other OTC
Aandelen
RTSL
US7534311052
Farmaceutische producten
Omzet 2021 | 0 0 | Omzet 2022 | - | Marktkapitalisatie | 5,82 mln. 5,43 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -2 mln. -1,86 mln. | Nettowinst (verlies) 2022 | -1 mln. -932K | EV/omzet 2021 | 93.978.853.933 x |
Nettoschuld 2021 | 1,79 mln. 1,67 mln. | Nettoschuld 2022 | 3,83 mln. 3,57 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-16,6
x | K/w-verhouding 2022 |
-3,24
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 75,41% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Donal Schmidt
CEO | Chief Executive Officer | 63 | 15-11-19 |
D. Watler
DFI | Director of Finance/CFO | 75 | 15-11-19 |
Sean P. Berrier
PRN | Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
D. Watler
DFI | Director of Finance/CFO | 75 | 15-11-19 |
Donal Schmidt
CEO | Chief Executive Officer | 63 | 15-11-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,33% | 6,11 mld. | |
-18,38% | 4,35 mld. | |
-9,17% | 3,18 mld. | |
+3,98% | 3,16 mld. | |
-3,41% | 2,51 mld. | |
+48,74% | 1,98 mld. | |
-4,82% | 1,74 mld. | |
-1,24% | 1,63 mld. | |
-8,96% | 1,6 mld. |